Scott Richard Gilbertson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott Richard Gilbertson has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Debananda Pati
Baylor College of Medicine 1 Texas Children’s Cancer Center, Department of Pediatrics, Molecular and Cellular Biology, Dan L. Duncan Cancer Center Houston, Texas
15 shared publications - Gaye N. Jenkins
Baylor College of Medicine 1 Texas Children’s Cancer Center, Department of Pediatrics, Molecular and Cellular Biology, Dan L. Duncan Cancer Center Houston, Texas
12 shared publications - Mary Perez
Baylor College of Medicine 1 Texas Children’s Cancer Center, Department of Pediatrics, Molecular and Cellular Biology, Dan L. Duncan Cancer Center Houston, Texas
12 shared publications - Nenggang Zhang
Baylor College of Medicine 1 Texas Children’s Cancer Center, Department of Pediatrics, Molecular and Cellular Biology, Dan L. Duncan Cancer Center Houston, Texas
12 shared publications - Terzah M. Horton
Baylor College of Medicine; Texas Children's Hospital, Houston, Texas, United States
12 shared publications - Kathryn A. Cunningham
University of Texas Medical Branch
3 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Springer Nature in Leukemia
- p. 1-15
Cheminformatic identification of small molecules targeting acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor prognosis and high relapse rates when treated with cytotoxic chemotherapeutics. Previously, we identified a family of small molecules that modulate mitochondrial function, referred to as PS127-family compounds. These drugs were selectively toxic to AML and were characterized by two predicted functions: apoptotic agonism and thioredoxin/glutathione reductase inhibition. Here, we uncovered a third critical predicted function, autophagic induction. Using a cheminformatic screen of ~4.2 million compounds for molecules with high predicted probability for all three functions, we found and validated hits that selectively killed AML cells, activated apoptosis, were dependent upon autophagic activation, and compromised glutathione metabolism by interfering with glutathione reductase, all of which are consistent with predictions. Compound treatment increased pools of cytosolic and mitochondrial ROS, decreased oxygen consumption, and reduced ATP synthesis. Structurally unrelated compounds caused the same phenotypes, validating our approach of screening for predicted function. Finally, we also observed strong synergy between these compounds and midostaurin and venetoclax, underscoring their therapeutic potential. Key phenotypes, including the compounds’ impact on glutathione metabolism and synergy with doxorubicin and midostaurin, were confirmed in AML-patient-derived primary cells, validating the potential of these compounds for the development of future AML treatments.
- 27 August 2026
- Published by Springer Nature in Leukemia
- p. 1-15
Open AccessCheminformatic identification of small molecules targeting acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor prognosis and high relapse rates when treated with cytotoxic chemotherapeutics. Previously, we identified a family of small molecules that modulate mitochondrial function, referred to as PS127-family compounds. These drugs were selectively toxic to AML and were characterized by two predicted functions: apoptotic agonism and thioredoxin/glutathione reductase inhibition. Here, we uncovered a third critical predicted function, autophagic induction. Using a cheminformatic screen of ~4.2 million compounds for molecules with high predicted probability for all three functions, we found and validated hits that selectively killed AML cells, activated apoptosis, were dependent upon autophagic activation, and compromised glutathione metabolism by interfering with glutathione reductase, all of which are consistent with predictions. Compound treatment increased pools of cytosolic and mitochondrial ROS, decreased oxygen consumption, and reduced ATP synthesis. Structurally unrelated compounds caused the same phenotypes, validating our approach of screening for predicted function. Finally, we also observed strong synergy between these compounds and midostaurin and venetoclax, underscoring their therapeutic potential. Key phenotypes, including the compounds’ impact on glutathione metabolism and synergy with doxorubicin and midostaurin, were confirmed in AML-patient-derived primary cells, validating the potential of these compounds for the development of future AML treatments.
- Open Access
- 11 August 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (3) , 201321
StagX1, an Isoquinolinone Compound, Selectively Targets CES1-positive Ewing Sarcoma Cells as a Potential Therapeutic Agent
- 11 August 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (3) , 201321
Open AccessStagX1, an Isoquinolinone Compound, Selectively Targets CES1-positive Ewing Sarcoma Cells as a Potential Therapeutic Agent
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S1 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S1 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S8 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S8 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S2 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S2 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S4 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S4 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Ewing sarcoma is a rare and aggressive pediatric malignancy with limited therapeutic options, particularly for relapsed or refractory cases, highlighting the urgent need for innovative treatment strategies. In this study, we identify endoplasmic reticulum stress (ERS) and the unfolded protein response (UPR) as critical therapeutic vulnerabilities in Ewing sarcoma and introduce 4-(heptyloxy)phenol (AC-45594) as a novel small-molecule agent that exploits these stress pathways. AC-45594 selectively inhibited the growth of Ewing sarcoma cells among 13 cancer and 6 noncancerous cell lines, demonstrating marked tumor specificity. Structure–activity relationship studies revealed that both the phenolic hydroxyl group and an optimal alkoxy chain length (7–9 carbon atoms) are essential for its activity. Mechanistically, AC-45594 induces ERS, activates UPR, and drives a shift from adaptive to terminal stress signaling, culminating in apoptosis of Ewing sarcoma cells. Proteomic and gene expression analyses further supported the selective activation of proapoptotic UPR signaling. These findings establish ERS and UPR as actionable targets in Ewing sarcoma and position AC-45594 as a first-in-class compound capable of selectively inducing stress-driven cell death. This work lays the foundation for a new class of therapeutics targeting maladaptive stress responses in pediatric sarcomas and potentially other hard-to-treat cancers.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Ewing sarcoma is a rare and aggressive pediatric malignancy with limited therapeutic options, particularly for relapsed or refractory cases, highlighting the urgent need for innovative treatment strategies. In this study, we identify endoplasmic reticulum stress (ERS) and the unfolded protein response (UPR) as critical therapeutic vulnerabilities in Ewing sarcoma and introduce 4-(heptyloxy)phenol (AC-45594) as a novel small-molecule agent that exploits these stress pathways. AC-45594 selectively inhibited the growth of Ewing sarcoma cells among 13 cancer and 6 noncancerous cell lines, demonstrating marked tumor specificity. Structure–activity relationship studies revealed that both the phenolic hydroxyl group and an optimal alkoxy chain length (7–9 carbon atoms) are essential for its activity. Mechanistically, AC-45594 induces ERS, activates UPR, and drives a shift from adaptive to terminal stress signaling, culminating in apoptosis of Ewing sarcoma cells. Proteomic and gene expression analyses further supported the selective activation of proapoptotic UPR signaling. These findings establish ERS and UPR as actionable targets in Ewing sarcoma and position AC-45594 as a first-in-class compound capable of selectively inducing stress-driven cell death. This work lays the foundation for a new class of therapeutics targeting maladaptive stress responses in pediatric sarcomas and potentially other hard-to-treat cancers.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S3 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S3 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S9 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S9 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S6 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma
Figure S6 from Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma